Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 298

1.

Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study.

Beghetti M, Channick RN, Chin KM, Di Scala L, Gaine S, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin VV, Preiss R, Rubin LJ, Simonneau G, Sitbon O, Tapson VF, Galiè N.

Eur J Heart Fail. 2019 Jan 11. doi: 10.1002/ejhf.1375. [Epub ahead of print]

PMID:
30632656
2.

Golden Ratio and the Proportionality Between Pulmonary Pressure Components in Pulmonary Arterial Hypertension.

Chemla D, Boulate D, Weatherald J, Lau EMT, Attal P, Savale L, Montani D, Fadel E, Mercier O, Sitbon O, Humbert M, Hervé P.

Chest. 2018 Dec 27. pii: S0012-3692(18)32893-9. doi: 10.1016/j.chest.2018.12.006. [Epub ahead of print]

PMID:
30594558
3.

Clinical trial design and new therapies for pulmonary arterial hypertension.

Sitbon O, Gomberg-Maitland M, Granton J, Lewis MI, Mathai SC, Rainisio M, Stockbridge NL, Wilkins MR, Zamanian RT, Rubin LJ.

Eur Respir J. 2019 Jan 24;53(1). pii: 1801908. doi: 10.1183/13993003.01908-2018. Print 2019 Jan.

4.

Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis.

Rhodes CJ, Batai K, Bleda M, Haimel M, Southgate L, Germain M, Pauciulo MW, Hadinnapola C, Aman J, Girerd B, Arora A, Knight J, Hanscombe KB, Karnes JH, Kaakinen M, Gall H, Ulrich A, Harbaum L, Cebola I, Ferrer J, Lutz K, Swietlik EM, Ahmad F, Amouyel P, Archer SL, Argula R, Austin ED, Badesch D, Bakshi S, Barnett C, Benza R, Bhatt N, Bogaard HJ, Burger CD, Chakinala M, Church C, Coghlan JG, Condliffe R, Corris PA, Danesino C, Debette S, Elliott CG, Elwing J, Eyries M, Fortin T, Franke A, Frantz RP, Frost A, Garcia JGN, Ghio S, Ghofrani HA, Gibbs JSR, Harley J, He H, Hill NS, Hirsch R, Houweling AC, Howard LS, Ivy D, Kiely DG, Klinger J, Kovacs G, Lahm T, Laudes M, Machado RD, Ross RVM, Marsolo K, Martin LJ, Moledina S, Montani D, Nathan SD, Newnham M, Olschewski A, Olschewski H, Oudiz RJ, Ouwehand WH, Peacock AJ, Pepke-Zaba J, Rehman Z, Robbins I, Roden DM, Rosenzweig EB, Saydain G, Scelsi L, Schilz R, Seeger W, Shaffer CM, Simms RW, Simon M, Sitbon O, Suntharalingam J, Tang H, Tchourbanov AY, Thenappan T, Torres F, Toshner MR, Treacy CM, Vonk Noordegraaf A, Waisfisz Q, Walsworth AK, Walter RE, Wharton J, White RJ, Wilt J, Wort SJ, Yung D, Lawrie A, Humbert M, Soubrier F, Trégouët DA, Prokopenko I, Kittles R, Gräf S, Nichols WC, Trembath RC, Desai AA, Morrell NW, Wilkins MR; UK NIHR BioResource Rare Diseases Consortium; UK PAH Cohort Study Consortium; US PAH Biobank Consortium.

Lancet Respir Med. 2018 Dec 5. pii: S2213-2600(18)30409-0. doi: 10.1016/S2213-2600(18)30409-0. [Epub ahead of print]

5.

Chronic blood exchange transfusions in the management of pre-capillary pulmonary hypertension complicating sickle cell disease.

Turpin M, Chantalat-Auger C, Parent F, Driss F, Lionnet F, Habibi A, Maître B, Huertas A, Jaïs X, Weatherald J, Montani D, Sitbon O, Simonneau G, Galactéros F, Humbert M, Bartolucci P, Savale L.

Eur Respir J. 2018 Oct 10;52(4). pii: 1800272. doi: 10.1183/13993003.00272-2018. Print 2018 Oct.

PMID:
30305330
6.

Haemodynamics and serial risk assessment in systemic sclerosis associated pulmonary arterial hypertension.

Weatherald J, Boucly A, Launay D, Cottin V, Prévot G, Bourlier D, Dauphin C, Chaouat A, Savale L, Jaïs X, Jevnikar M, Traclet J, De Groote P, Simonneau G, Hachulla E, Mouthon L, Montani D, Humbert M, Sitbon O.

Eur Respir J. 2018 Oct 18;52(4). pii: 1800678. doi: 10.1183/13993003.00678-2018. Print 2018 Oct.

PMID:
30209196
7.

[Liver diseases and pulmonary vascular disorders].

Riou M, Jutant EM, Mignard X, Canuet M, Humbert M, Sitbon O, Savale L, Montani D.

Rev Med Interne. 2018 Dec;39(12):925-934. doi: 10.1016/j.revmed.2018.07.015. Epub 2018 Aug 30. Review. French.

PMID:
30174113
8.

Pulmonary hypertension associated with neurofibromatosis type 1.

Jutant EM, Girerd B, Jaïs X, Savale L, O'Connell C, Perros F, Sitbon O, Humbert M, Montani D.

Eur Respir Rev. 2018 Aug 29;27(149). pii: 180053. doi: 10.1183/16000617.0053-2018. Print 2018 Sep 30. Review.

9.

Pharmacovigilance in a rare disease: example of the VIGIAPATH program in pulmonary arterial hypertension.

Chaumais MC, O'Connell C, Savale L, Guignabert C, Perros F, Jaïs X, Sitbon O, Humbert M, Montani D.

Int J Clin Pharm. 2018 Aug;40(4):790-794. doi: 10.1007/s11096-018-0712-y. Epub 2018 Aug 13.

PMID:
30101375
10.

Impact of the initiation of balloon pulmonary angioplasty program on referral of patients with chronic thromboembolic pulmonary hypertension to surgery.

Amsallem M, Guihaire J, Arthur Ataam J, Lamrani L, Boulate D, Mussot S, Fabre D, Taniguchi Y, Haddad F, Sitbon O, Jais X, Humbert M, Simonneau G, Mercier O, Brenot P, Fadel E.

J Heart Lung Transplant. 2018 Sep;37(9):1102-1110. doi: 10.1016/j.healun.2018.05.004. Epub 2018 May 24.

PMID:
30037729
11.

Risk stratification in pulmonary arterial hypertension.

Weatherald J, Boucly A, Sitbon O.

Curr Opin Pulm Med. 2018 Sep;24(5):407-415. doi: 10.1097/MCP.0000000000000510.

PMID:
30004992
12.

[Evaluation of cardiac MRI in the follow up assessment of patients with pulmonary arterial hypertension].

Chaouat A, Cherifi A, Sitbon O, Girerd N, Zysman M, Faure M, Mandry D, Mercy M, Guillaumot A, Fay R, Marie PY, Chabot F.

Rev Mal Respir. 2018 Sep;35(7):749-758. doi: 10.1016/j.rmr.2018.01.010. Epub 2018 Jun 23. French.

PMID:
29945811
13.

Clinical and Hemodynamic Correlates of Pulmonary Arterial Stiffness in Incident, Untreated Patients With Idiopathic Pulmonary Arterial Hypertension.

Chemla D, Weatherald J, Lau EMT, Savale L, Boucly A, Attal P, Jaïs X, Parent F, Girerd B, Simonneau G, Montani D, Humbert M, Sitbon O, Hervé P.

Chest. 2018 Oct;154(4):882-892. doi: 10.1016/j.chest.2018.06.015. Epub 2018 Jun 27.

PMID:
29940163
14.

Factors predicting outcome after pulmonary endarterectomy.

Tromeur C, Jaïs X, Mercier O, Couturaud F, Montani D, Savale L, Jevnikar M, Weatherald J, Sitbon O, Parent F, Fabre D, Mussot S, Dartevelle P, Humbert M, Simonneau G, Fadel E.

PLoS One. 2018 Jun 21;13(6):e0198198. doi: 10.1371/journal.pone.0198198. eCollection 2018.

15.

Association Between BMI and Obesity With Survival in Pulmonary Arterial Hypertension.

Weatherald J, Huertas A, Boucly A, Guignabert C, Taniguchi Y, Adir Y, Jevnikar M, Savale L, Jaïs X, Peng M, Simonneau G, Montani D, Humbert M, Sitbon O.

Chest. 2018 Oct;154(4):872-881. doi: 10.1016/j.chest.2018.05.006. Epub 2018 May 22.

PMID:
29800550
16.

Clinical phenotypes and survival of pre-capillary pulmonary hypertension in systemic sclerosis.

Launay D, Montani D, Hassoun PM, Cottin V, Le Pavec J, Clerson P, Sitbon O, Jaïs X, Savale L, Weatherald J, Sobanski V, Mathai SC, Shafiq M, Cordier JF, Hachulla E, Simonneau G, Humbert M.

PLoS One. 2018 May 15;13(5):e0197112. doi: 10.1371/journal.pone.0197112. eCollection 2018.

17.

Age, risk and outcomes in idiopathic pulmonary arterial hypertension.

Hoeper MM, Boucly A, Sitbon O.

Eur Respir J. 2018 May 3;51(5). pii: 1800629. doi: 10.1183/13993003.00629-2018. Print 2018 May. No abstract available.

PMID:
29724788
18.

Natural History over 8 Years of Pulmonary Vascular Disease in a Patient Carrying Biallelic EIF2AK4 Mutations.

Montani D, Dorfmüller P, Girerd B, Le Pavec J, Fadel E, Simonneau G, Sitbon O, Humbert M.

Am J Respir Crit Care Med. 2018 Aug 15;198(4):537-541. doi: 10.1164/rccm.201802-0317LE. No abstract available.

PMID:
29702008
19.

Risk assessment in pulmonary arterial hypertension.

Boucly A, Weatherald J, Humbert M, Sitbon O.

Eur Respir J. 2018 Mar 29;51(3). pii: 1800279. doi: 10.1183/13993003.00279-2018. Print 2018 Mar. No abstract available.

PMID:
29599118
20.

Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial.

Souza R, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Le Brun FO, Mehta S, Perchenet L, Pulido T, Sastry BKS, Sitbon O, Torbicki A, Rubin LJ, Simonneau G.

PLoS One. 2018 Mar 28;13(3):e0193226. doi: 10.1371/journal.pone.0193226. eCollection 2018.

21.

[Pulmonary veno-occlusive disease].

Boucly A, Girerd B, Bourlier D, Nemlaghi S, Caliez J, Savale L, Jaïs X, Dorfmüller P, Simonneau G, Sitbon O, Humbert M, Montani D.

Rev Mal Respir. 2018 Feb;35(2):160-170. doi: 10.1016/j.rmr.2017.11.005. Epub 2018 Mar 1. Review. French.

PMID:
29501213
22.

Association between Rheumatoid Arthritis and Pulmonary Hypertension: Data from the French Pulmonary Hypertension Registry.

Montani D, Henry J, O'Connell C, Jaïs X, Cottin V, Launay D, Habib G, Bourdin A, Jevnikar M, Savale L, Rottat L, Simonneau G, Sitbon O, Humbert M, Allanore Y.

Respiration. 2018;95(4):244-250. doi: 10.1159/000485631. Epub 2018 Feb 28.

PMID:
29490304
23.

Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality.

McLaughlin VV, Hoeper MM, Channick RN, Chin KM, Delcroix M, Gaine S, Ghofrani HA, Jansa P, Lang IM, Mehta S, Pulido T, Sastry BKS, Simonneau G, Sitbon O, Souza R, Torbicki A, Tapson VF, Perchenet L, Preiss R, Verweij P, Rubin LJ, Galiè N.

J Am Coll Cardiol. 2018 Feb 20;71(7):752-763. doi: 10.1016/j.jacc.2017.12.010.

24.

RV Fractional Area Change and TAPSE as Predictors of Severe Right Ventricular Dysfunction in Pulmonary Hypertension: A CMR Study.

Hoette S, Creuzé N, Günther S, Montani D, Savale L, Jaïs X, Parent F, Sitbon O, Rochitte CE, Simonneau G, Humbert M, Souza R, Chemla D.

Lung. 2018 Apr;196(2):157-164. doi: 10.1007/s00408-018-0089-7. Epub 2018 Feb 12.

PMID:
29435740
25.

Outcome of Portopulmonary Hypertension After Liver Transplantation: Perhaps Not So Optimistic.

Savale L, Duclos-Vallée JC, Sitbon O.

Transplantation. 2018 Apr;102(4):e190-e191. doi: 10.1097/TP.0000000000002112. No abstract available.

PMID:
29401123
26.

Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study.

Coghlan JG, Channick R, Chin K, Di Scala L, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin V, Preiss R, Rubin LJ, Simonneau G, Sitbon O, Tapson VF, Gaine S.

Am J Cardiovasc Drugs. 2018 Feb;18(1):37-47. doi: 10.1007/s40256-017-0262-z.

27.

The Low-Risk Profile in Pulmonary Arterial Hypertension. Time for a Paradigm Shift to Goal-oriented Clinical Trial Endpoints?

Weatherald J, Boucly A, Sahay S, Humbert M, Sitbon O.

Am J Respir Crit Care Med. 2018 Apr 1;197(7):860-868. doi: 10.1164/rccm.201709-1840PP. No abstract available.

PMID:
29256625
28.

Acute decompensated pulmonary hypertension.

Savale L, Weatherald J, Jaïs X, Vuillard C, Boucly A, Jevnikar M, Montani D, Mercier O, Simonneau G, Fadel E, Sitbon O, Humbert M.

Eur Respir Rev. 2017 Nov 15;26(146). pii: 170092. doi: 10.1183/16000617.0092-2017. Print 2017 Dec 31. Review.

29.

Pulmonary vascular remodeling patterns and expression of general control nonderepressible 2 (GCN2) in pulmonary veno-occlusive disease.

Nossent EJ, Antigny F, Montani D, Bogaard HJ, Ghigna MR, Lambert M, Thomas de Montpréville V, Girerd B, Jaïs X, Savale L, Mercier O, Fadel E, Soubrier F, Sitbon O, Simonneau G, Vonk Noordegraaf A, Humbert M, Perros F, Dorfmüller P.

J Heart Lung Transplant. 2018 May;37(5):647-655. doi: 10.1016/j.healun.2017.09.022. Epub 2017 Oct 4.

PMID:
29108819
30.

Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI2) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study.

Preston IR, Channick RN, Chin K, Di Scala L, Farber HW, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin VV, Preiss R, Simonneau G, Sitbon O, Tapson VF, Rubin LJ.

J Heart Lung Transplant. 2018 Mar;37(3):401-408. doi: 10.1016/j.healun.2017.09.024. Epub 2017 Oct 2.

PMID:
29096938
31.

Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension.

Weatherald J, Boucly A, Chemla D, Savale L, Peng M, Jevnikar M, Jaïs X, Taniguchi Y, O'Connell C, Parent F, Sattler C, Hervé P, Simonneau G, Montani D, Humbert M, Adir Y, Sitbon O.

Circulation. 2018 Feb 13;137(7):693-704. doi: 10.1161/CIRCULATIONAHA.117.029254. Epub 2017 Oct 25.

PMID:
29070502
32.

Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension.

Boucly A, Cottin V, Nunes H, Jaïs X, Tazi A, Prévôt G, Reynaud-Gaubert M, Dromer C, Viacroze C, Horeau-Langlard D, Pison C, Bergot E, Traclet J, Weatherald J, Simonneau G, Valeyre D, Montani D, Humbert M, Sitbon O, Savale L.

Eur Respir J. 2017 Oct 19;50(4). pii: 1700465. doi: 10.1183/13993003.00465-2017. Print 2017 Oct.

PMID:
29051269
33.

Portopulmonary Hypertension.

Savale L, Watherald J, Sitbon O.

Semin Respir Crit Care Med. 2017 Oct;38(5):651-661. doi: 10.1055/s-0037-1606251. Epub 2017 Oct 17. Review. No abstract available.

PMID:
29041033
34.

Medical Treatment of Pulmonary Arterial Hypertension.

Sahay S, Humbert M, Sitbon O.

Semin Respir Crit Care Med. 2017 Oct;38(5):686-700. doi: 10.1055/s-0037-1607208. Epub 2017 Oct 15. Review. No abstract available.

PMID:
29032569
35.

Are indexed values better for defining exercise pulmonary hypertension?

Weatherald J, Boucly A, Lau E, Godinas L, Savale L, Jaïs X, Montani D, Sitbon O, Simonneau G, Humbert M, Chemla D, Hervé P.

Eur Respir J. 2017 Sep 9;50(3). pii: 1700240. doi: 10.1183/13993003.00240-2017. Print 2017 Sep. No abstract available.

PMID:
28889109
36.

Exertional dyspnoea in pulmonary arterial hypertension.

Dumitrescu D, Sitbon O, Weatherald J, Howard LS.

Eur Respir Rev. 2017 Sep 6;26(145). pii: 170039. doi: 10.1183/16000617.0039-2017. Print 2017 Sep 30. Review.

37.

Pulmonary Arterial Hypertension Associated With Systemic Lupus Erythematosus: Results From the French Pulmonary Hypertension Registry.

Hachulla E, Jais X, Cinquetti G, Clerson P, Rottat L, Launay D, Cottin V, Habib G, Prevot G, Chabanne C, Foïs E, Amoura Z, Mouthon L, Le Guern V, Montani D, Simonneau G, Humbert M, Sobanski V, Sitbon O; French Collaborators Recruiting Members(∗).

Chest. 2018 Jan;153(1):143-151. doi: 10.1016/j.chest.2017.08.014. Epub 2017 Aug 26.

PMID:
28851621
38.

Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension.

Gaine S, Chin K, Coghlan G, Channick R, Di Scala L, Galiè N, Ghofrani HA, Lang IM, McLaughlin V, Preiss R, Rubin LJ, Simonneau G, Sitbon O, Tapson VF, Hoeper MM.

Eur Respir J. 2017 Aug 17;50(2). pii: 1602493. doi: 10.1183/13993003.02493-2016. Print 2017 Aug.

39.

Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension.

Boucly A, Weatherald J, Savale L, Jaïs X, Cottin V, Prevot G, Picard F, de Groote P, Jevnikar M, Bergot E, Chaouat A, Chabanne C, Bourdin A, Parent F, Montani D, Simonneau G, Humbert M, Sitbon O.

Eur Respir J. 2017 Aug 3;50(2). pii: 1700889. doi: 10.1183/13993003.00889-2017. Print 2017 Aug.

40.

Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study.

Weatherald J, Chaumais MC, Savale L, Jaïs X, Seferian A, Canuet M, Bouvaist H, Magro P, Bergeron A, Guignabert C, Sitbon O, Simonneau G, Humbert M, Montani D.

Eur Respir J. 2017 Jul 27;50(1). pii: 1700217. doi: 10.1183/13993003.00217-2017. Print 2017 Jul.

41.

Dead-space ventilation is linked to exercise capacity and survival in distal chronic thromboembolic pulmonary hypertension.

Godinas L, Sattler C, Lau EM, Jaïs X, Taniguchi Y, Jevnikar M, Weatherald J, Sitbon O, Savale L, Montani D, Simonneau G, Humbert M, Laveneziana P, Garcia G.

J Heart Lung Transplant. 2017 Nov;36(11):1234-1242. doi: 10.1016/j.healun.2017.05.024. Epub 2017 May 22.

PMID:
28666570
42.

Validation of a risk assessment instrument for pulmonary arterial hypertension.

Weatherald J, Sitbon O, Humbert M.

Eur Heart J. 2018 Dec 14;39(47):4182-4185. doi: 10.1093/eurheartj/ehx301. No abstract available.

PMID:
28637288
43.

Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study.

Rhodes CJ, Wharton J, Ghataorhe P, Watson G, Girerd B, Howard LS, Gibbs JSR, Condliffe R, Elliot CA, Kiely DG, Simonneau G, Montani D, Sitbon O, Gall H, Schermuly RT, Ghofrani HA, Lawrie A, Humbert M, Wilkins MR.

Lancet Respir Med. 2017 Sep;5(9):717-726. doi: 10.1016/S2213-2600(17)30161-3. Epub 2017 Jun 15.

44.

Impact of High-Priority Allocation on Lung and Heart-Lung Transplantation for Pulmonary Hypertension.

Savale L, Le Pavec J, Mercier O, Mussot S, Jaïs X, Fabre D, O'Connell C, Montani D, Stephan F, Sitbon O, Simonneau G, Dartevelle P, Humbert M, Fadel E.

Ann Thorac Surg. 2017 Aug;104(2):404-411. doi: 10.1016/j.athoracsur.2017.02.034. Epub 2017 May 18.

PMID:
28527964
45.

Pulmonary hypertension due to left heart disease.

Berthelot E, Bailly MT, Hatimi SE, Robard I, Rezgui H, Bouchachi A, Montani D, Sitbon O, Chemla D, Assayag P.

Arch Cardiovasc Dis. 2017 Jun - Jul;110(6-7):420-431. doi: 10.1016/j.acvd.2017.01.010. Epub 2017 Apr 12. Review.

46.

SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension.

Galiè N, Jansa P, Pulido T, Channick RN, Delcroix M, Ghofrani HA, Le Brun FO, Mehta S, Perchenet L, Rubin LJ, Sastry BKS, Simonneau G, Sitbon O, Souza R, Torbicki A.

Eur Heart J. 2017 Apr 14;38(15):1147-1155. doi: 10.1093/eurheartj/ehx025.

47.

Outcome of adults with Eisenmenger syndrome treated with drugs specific to pulmonary arterial hypertension: A French multicentre study.

Hascoet S, Fournier E, Jaïs X, Le Gloan L, Dauphin C, Houeijeh A, Godart F, Iriart X, Richard A, Radojevic J, Amedro P, Bosser G, Souletie N, Bernard Y, Moceri P, Bouvaist H, Mauran P, Barre E, Basquin A, Karsenty C, Bonnet D, Iserin L, Sitbon O, Petit J, Fadel E, Humbert M, Ladouceur M.

Arch Cardiovasc Dis. 2017 May;110(5):303-316. doi: 10.1016/j.acvd.2017.01.006. Epub 2017 Mar 9.

48.

Gut-Lung Connection in Pulmonary Arterial Hypertension.

Ranchoux B, Bigorgne A, Hautefort A, Girerd B, Sitbon O, Montani D, Humbert M, Tcherakian C, Perros F.

Am J Respir Cell Mol Biol. 2017 Mar;56(3):402-405. doi: 10.1165/rcmb.2015-0404LE. No abstract available.

PMID:
28248132
49.

Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience.

Sitbon O, Vonk Noordegraaf A.

Eur Respir Rev. 2017 Jan 17;26(143). pii: 160055. doi: 10.1183/16000617.0055-2016. Print 2017 Jan. Review.

50.

Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study.

Montani D, Girerd B, Jaïs X, Levy M, Amar D, Savale L, Dorfmüller P, Seferian A, Lau EM, Eyries M, Le Pavec J, Parent F, Bonnet D, Soubrier F, Fadel E, Sitbon O, Simonneau G, Humbert M.

Lancet Respir Med. 2017 Feb;5(2):125-134. doi: 10.1016/S2213-2600(16)30438-6. Epub 2017 Jan 11.

PMID:
28087362

Supplemental Content

Loading ...
Support Center